Isoindolinone derivatives having a glutarimide nucleus and uses thereof
Isoindolinone derivatives with a glutarimide core address the side effect issues of thalidomide by targeting CRBN protein to degrade Ikaros/Aiolos and GSPT1, offering enhanced cancer cell cytotoxicity and therapeutic potential for leprosy and chronic graft-versus-host disease.
Patent Information
- Application Number
- JP2024527256
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-08
- Filing Date
- 2022-11-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing thalidomide derivatives used for treating leprosy, chronic graft-versus-host disease, inflammatory diseases, and cancer have significant side effects, necessitating the development of compounds that retain therapeutic efficacy while minimizing these adverse effects.
Development of isoindolinone derivatives with a glutarimide core, featuring specific aryl substituents, which exhibit enhanced activity against cancer cells and reduce side effects by targeting the CRBN protein to degrade Ikaros/Aiolos and GSPT1 proteins.
The isoindolinone derivatives effectively bind to CRBN protein, inducing the degradation of Ikaros/Aiolos and GSPT1, demonstrating superior cytotoxicity against various cancer cells and potential therapeutic benefits for leprosy, chronic graft-versus-host disease, and inflammatory diseases.
Smart Images

Figure 2024544507000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to an isoindolinone derivative having a glutarimide nucleus and uses thereof, and more particularly to an isoindolinone derivative compound having a glutarimide nucleus that exhibits preventive or therapeutic effects against leprosy, chronic graft-versus-host disease, inflammatory diseases, or cancer. [Background technology]
[0002] Thalidomide is a racemic compound sold under the trade name THALOMID® and the chemical names α-(N-phthalimido)glutarimide or 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione. Thalidomide was originally developed to treat morning sickness, but was discontinued due to its teratogenic effects. Thalidomide is currently approved in the United States for the treatment of erythema nodosum in humans (Patent Document 1: Korean Registered Patent No. 10-0671366).
[0003] Thalidomide has also been reported to be used in patients with leprosy, chronic graft-versus-host disease, rheumatoid arthritis, sarcoid disease, some inflammatory skin diseases, and inflammatory bowel disease, and it has been reported that thalidomide can be combined with other drugs to treat ischemia / reperfusion associated with cardiac and cerebral artery occlusion (U.S. Patent Publication No. 05643915).
[0004] More recently, thalidomide has been used to treat certain types of cancer, including refractory multiple myeloma, brain, melanoma, breast, colon, mesothelioma, and renal cell carcinoma. Thalidomide has also been reported to be used to prevent the development of doxorubicin-induced chronic cardiomyopathy in rats. Other reports of the use of thalidomide in the treatment of certain cancers include its use in combination with carboplatin in the treatment of glioblastoma multiforme. Thalidomide has also been reported to be used as an analgesic in the treatment of astrocytoma (Non-Patent Documents 1-4: Costa, PT et al., Blood, 92(Suppl 1, Pt 2), 235b, 1998; Marx, GM et al., Proc Am Soc Clin Oncol., 454a, 1999; Singhal, S. et al., N Engl J Med., 341(21), 1565-1571, 1999; Zwart, D., Arzneimittelforschung, 16(12), 1688-1689, 1966).
[0005] Thalidomide is also used for a variety of purposes, including the prevention and treatment of lupus nephritis, fibromyalgia, schizophrenia, central nervous system diseases, diabetes, and inflammatory diseases. However, it has a history of causing fatal side effects in pregnant women who take it, including the induction of birth defects in their children, and was removed from the market at the end of 1961.
[0006] Research is being actively conducted to develop derivatives of thalidomide that retain the various physiological benefits of thalidomide while eliminating the serious side effects. Intracellular protein degradation is mainly mediated by the ubiquitin-proteasome system (UPS). Proteins called E1, E2, and E3 ligases transfer ubiquitin (Ub), which consists of 76 amino acids, to the protein to be degraded (substrate) to perform polyubiquitination, and the 26S proteasome recognizes it and degrades the protein.
[0007] Lenalidomide and pomalidomide, derivatives of thalidomide known as immunomodulatory drugs (IMiDs), are used as treatments for multiple myeloma by binding to an E3 ligase called cerebron (CRBN) and inducing the degradation of zinc finger transcription factors IKZF1 and IKZF3. In particular, lenalidomide degrades CK-1a and is used as a treatment for 5q-del-MDS patients, and is one of the best-selling anticancer drugs worldwide.
[0008] GSPT1 is a GTPase that forms a complex with eRF1 under GTP-bound conditions and binds to the stop codon of mRNA. When GTP is converted to GDP, GSPT1 is separated from eRF1 and is involved in protein cleavage by eRF1 (Non-Patent Document 5: Cell Reports, 2014, 8, 59-65).
[0009] It is known that GSPT1 knockdown reduces the phosphorylation of 4E-BP1 and the kinase S6K1, suppressing mTOR activity and inducing G1 arrest (Non-Patent Document 6: Molecular and Cellular Biology, 2007, 27, 5619).
[0010] It has been confirmed that GSPT1 is overexpressed in a colon cancer cell line (HCT116) and is involved in cell growth and migration, and that knocking down GSPT1 induces cell death by suppressing the expression of c-myc, survivin and Bcl2L15 (Non-patent literature 7: Biomed. Pharmacother. 2015, 74, 138-144).
[0011] In addition, Celgene has reported that the lenalidomide-derived CC-885 compound degrades the new protein GSPT1 and exhibits high cytotoxicity in various blood cancer cells. Through optimization research, the company has derived the CC-90009 substance, which is currently undergoing clinical testing in patients with R and R-AML (Non-patent literature 8: Nature, 2016, 14, 252; Blood, 2021).
[0012] We developed a novel piperidine-2,6-dione-based thalidomide derivative that retains the physiological activity of thalidomide but does not have the side effects of thalidomide, and confirmed that this compound promotes the proteolysis of GSPT1 protein and Aiolos. In addition, it was confirmed that the developed compounds have sufficient cytotoxicity in cancer cells, and in particular, compounds substituted with urea derivatives and triazine derivative compounds have superior cytotoxic activity against cancer cells (Patent Document 2: Korean Patent Publication No. 10-2020-0054046).
[0013] In addition, it has been reported that 5-substituted isoindoline compounds exhibit antiproliferative effects against various cancer cells including those of prostate, colon, pancreas, and breast, in addition to TNF-α inhibitory effects and IL-2 production effects (Patent Document 3: Korean Patent Publication No. 10-2011-0019761), and that isoindoline compounds are effective against various diseases including cancer by controlling angiogenesis, inhibiting the production of specific cytokines such as TNF-α, and stimulating the production of specific cytokines such as IL-10 (Patent Document 4: Korean Patent Registration No. 10-1696938).
[0014] In addition, a method for predicting and treating various diseases, including cancer, by administering a compound having isoindolinone and glutarimide has been reported (Patent Document 5: Korean Patent Publication No. 10-2018-0095094), and it has been reported that a compound having an aminoamide linker acts as a regulator of various protein activities such as cytokines, TNF-α, and GSPT1, and is effective in treating various diseases such as inflammatory diseases and cancer (Patent Document 6: Australian Patent Publication No. 2019284608).
[0015] The present inventors have confirmed that, in comparison with the compounds developed in the existing prior patents, the compounds represented by Chemical Formula 1 of the present invention having a glutarimide group and an isoindolinone structure have excellent activity when an aryl substituent is present in the heteroaryl, and in particular, when the heteroaryl is a bicyclic heteroaryl or a monocyclic heteroaryl having an aryl group substituted therein, the compounds exhibit excellent physiological activity against cancer cells compared with the monocyclic heteroaryl, and have thus completed the present invention. [Prior art documents] [Patent documents]
[0016] [Patent Document 1] Korean Patent No. 10-0671366 [Patent Document 2] Korean Patent No. 10-2020-0054046 [Patent Document 3] Korean Patent Publication No. 10-2011-0019761 [Patent Document 4] Korean Patent No. 10-1696938 [Patent Document 5] Korean Patent Publication No. 10-2018-0095094 [Patent Document 6] Australian Patent Publication No. 2019284608 [Non-patent literature]
[0017] [Non-Patent Document 1] Costa, PT et al., Blood, 92(Suppl 1, Pt 2), 235b, 1998 [Non-Patent Document 2] Marx, GMet al., Proc Am Soc Clin Oncol., 454a, 1999. [Non-Patent Document 3] Singhal, S. et al., N Engl J Med., 341(21), 1565-1571, 1999 [Non-Patent Document 4] Zwart, D., Arzneimittelforschung, 16(12), 1688-1689, 1966 [Non-Patent Document 5] Cell Reports,2014,8,59-65 [Non-Patent Document 6] Molecular and cellular biology,2007,27,5619 [Non-Patent Document 7] Biomed.Pharmacother.2015,74,138-144 [Non-Patent Document 8] Nature, 2016, 14, 252; Blood, 2021 Summary of the Invention [Problem to be solved by the invention]
[0018] The present inventors have developed isoindolinone derivative compounds having a glutarimide mother nucleus which exhibit preventive or therapeutic effects against leprosy, chronic graft-versus-host disease, inflammatory diseases or cancer, and have completed the present invention by evaluating their activity.
[0019] Accordingly, an object of the present invention is to provide a compound represented by the following Chemical Formula 1 or a pharma- ceutically acceptable salt thereof: [Means for solving the problem]
[0020] The present invention relates to a compound represented by the following chemical formula 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof:
[0021] [ka]
[0022] During the ceremony,
[0023] l is an integer from 0 to 3;
[0024] n is an integer of 0 or 1;
[0025] p is an integer of 1 or 2;
[0026] R1 is C 5-13 Heteroaryl, C 6-10 Aryl, C 4-10 Cycloalkyl, C 4-10 is heterocycloalkyl;
[0027] R2 is independently hydrogen, halogen, ketone, C 1-5 Alkyl, C 1-3 Alkoxy, HaloC 1-3 Alkyl, haloC 1-3 Alkoxy, C 3-6 substituted with one or more substituents selected from the group consisting of cycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted benzyl;
[0028] wherein the substituted phenyl or benzyl is halogen or C 1-5 substituted with one or more substituents selected from the group consisting of alkyl;
[0029] R3 is substituted with hydrogen or deuterium (D).
[0030] In addition, the present invention preferably relates to a compound represented by the formula 1:
[0031] l is an integer from 0 to 3;
[0032] n is an integer of 0 or 1;
[0033] p is an integer of 1 or 2;
[0034] R1 is substituted with one substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, indazolyl, benzimidazolyl, benzofuranyl, benzopyridinyl, benzopyranyl, benzopyridazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, and naphthofuranyl;
[0035] R2 is independently hydrogen, halogen, ketone, C 1-5 Alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, C 1-3 Alkoxy, HaloC 1-3 Alkyl and haloC 1-3 substituted with one or more substituents selected from the group consisting of alkoxy;
[0036] wherein the substituted phenyl or benzyl is halogen or C 1-5 substituted with one or more substituents selected from the group consisting of alkyl;
[0037] R3 is substituted with hydrogen or deuterium (D);
[0038] The present invention relates to a compound, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, characterized in that
[0039] In addition, the present invention preferably relates to a compound represented by the formula 1:
[0040] l is an integer from 0 to 3;
[0041] n is an integer of 0 or 1;
[0042] p is an integer of 1 or 2;
[0043] R1 is C 5-10 is heteroaryl;
[0044] R2 is substituted with one or more substituents selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted benzyl;
[0045] wherein the substituted phenyl or benzyl is halogen or C 1-5 alkyl substituted with one or more substituents selected from the group consisting of:
[0046] R3 is substituted with hydrogen or deuterium (D);
[0047] The present invention relates to a compound, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, characterized in that
[0048] In addition, the present invention preferably relates to a compound represented by the formula 1:
[0049] l is an integer from 0 to 3;
[0050] n is an integer of 0 or 1;
[0051] p is an integer of 1 or 2;
[0052] R1 is substituted with one substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, indazolyl, benzimidazolyl, benzofuranyl, benzopyridinyl, benzopyranyl, benzopyridazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, and naphthofuranyl:
[0053] R2 is substituted with one or more substituents selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted benzyl;
[0054] wherein the substituted phenyl or benzyl is halogen or C 1-5 alkyl substituted with one or more substituents selected from the group consisting of:
[0055] R3 is substituted with hydrogen or deuterium (D);
[0056] The present invention relates to a compound, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, characterized in that
[0057] More specifically, the compound of the above-mentioned formula 1 of the present invention is exemplified as follows:
[0058] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 1);
[0059] 3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 2);
[0060] 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide (compound 3);
[0061] 5,6-dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 4);
[0062] 3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 5);
[0063] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide (compound 6);
[0064] 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide (compound 7);
[0065] 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 8);
[0066] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-2-carboxamide (compound 9);
[0067] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]isoxazole-3-carboxamide (compound 10);
[0068] 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide (compound 11);
[0069] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 12);
[0070] 3-(3,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 13);
[0071] 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrrole-2-carboxamide (compound 14);
[0072] 1-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (compound 15);
[0073] 5,6-Dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide (compound 16);
[0074] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide (compound 17);
[0075] 4-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide (compound 18);
[0076] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide (compound 19);
[0077] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)pyrimidine-2-carboxamide (compound 20);
[0078] 1-benzyl-5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 21);
[0079] 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide (compound 22);
[0080] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-5-phenyl-1H-pyrazole-3-carboxamide (compound 23);
[0081] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-3-phenyl-1H-pyrazole-5-carboxamide (compound 24);
[0082] 5-(2,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 25);
[0083] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]thiazole-2-carboxamide (compound 26);
[0084] 4-Bromo-3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 27);
[0085] 5-(2,5-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 28);
[0086] 5-(2,4-dimethylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 29);
[0087] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-3-carboxamide (compound 30);
[0088] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methylpicolinamide (compound 31);
[0089] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 32);
[0090] 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]oxazole-2-carboxamide (compound 33);
[0091] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 34);
[0092] 3-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrazole-5-carboxamide (compound 35);
[0093] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-indazole-3-carboxamide (compound 36);
[0094] 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-imidazole-2-carboxamide (compound 37);
[0095] 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide (compound 38);
[0096] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-4-phenyl-1H-pyrrole-2-carboxamide (compound 39);
[0097] 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide (compound 40);
[0098] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide (compound 41);
[0099] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide (compound 42);
[0100] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-(4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 43);
[0101] 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]thiazole-2-carboxamide (compound 44);
[0102] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methyl-4-phenylpicolinamide (compound 45);
[0103] 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 46);
[0104] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-phenylpyrazine-2-carboxamide (compound 47);
[0105] 3-(2-chloro-6-fluorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methylisoxazole-4-carboxamide (compound 48);
[0106] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-phenyl-1H-pyrazole-5-carboxamide (compound 49);
[0107] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide (compound 50);
[0108] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-4-carboxamide (compound 51);
[0109] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-2-carboxamide (compound 52);
[0110] 1-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)cyclopentane-1-carboxamide (compound 53);
[0111] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenylcyclopentane-1-carboxamide (compound 54);
[0112] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-1-phenylpyrrolidine-3-carboxamide (compound 55);
[0113] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzofuran-2-carboxamide (compound 56);
[0114] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxy-1H-indole-2-carboxamide (compound 57);
[0115] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[b]thiophene-2-carboxamide (compound 58);
[0116] 7-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-hydroxyquinoline-3-carboxamide (compound 59);
[0117] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-2H-chromene-3-carboxamide (compound 60);
[0118] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)chromene-4-carboxamide (compound 61);
[0119] 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide (compound 62);
[0120] 5-(3-chlorophenyl)-1-cyclopropyl-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 63);
[0121] 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide (compound 64);
[0122] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzo[b]thiophene-2-carboxamide (compound 65);
[0123] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide (compound 66);
[0124] 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide (compound 67);
[0125] 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzo[b]thiophene-2-carboxamide (compound 68);
[0126] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5,6-dimethoxybenzo[b]thiophene-2-carboxamide (compound 69);
[0127] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 70);
[0128] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 71);
[0129] 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 72);
[0130] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 73);
[0131] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methoxybenzo[b]thiophene-2-carboxamide (compound 74);
[0132] 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 75);
[0133] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 76);
[0134] 4-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 77);
[0135] 7-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 78);
[0136] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-fluoro-3-methylbenzo[b]thiophene-2-carboxamide (compound 79);
[0137] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide (compound 80);
[0138] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzofuran-2-carboxamide (compound 81);
[0139] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-methoxybenzofuran-2-carboxamide (compound 82);
[0140] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzofuran-2-carboxamide (compound 83);
[0141] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3,6-dimethylbenzofuran-2-carboxamide (compound 84);
[0142] 5-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide (compound 85); and
[0143] N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)naphtho[2,1-b]furan-2-carboxamide (Compound 86);
[0144] The compound of the present invention represented by the above Chemical Formula 1 can be prepared by the methods of the following Reaction Schemes 1 and 2.
[0145] TIFF2024544507000003.tif64166
[0146] TIFF2024544507000004.tif32166
[0147] In the above reaction scheme 1, the methods for producing the respective intermediates 2 to 5 are as follows.
[0148] 1) Synthesis of methyl 4-cyano-2-methylbenzoate (intermediate 2)
[0149] Methyl 4-bromo-2-methylbenzoate (3 g, 13.10 mmol) was dissolved in DMF (40 ml), followed by the addition of Pd2(dba)3 (0.480 g, 0.524 mmol), dppf (0.436 g, 0.786 mmol), and zinc cyanide (1.692 g, 14.41 mmol) and stirred under nitrogen gas for 30 minutes. The temperature was then raised to 130°C and stirred for 3 hours. After the reaction was complete, the mixture was filtered through a Celite pad. (R) The mixture was filtered with hexane and washed several times with DMF. The filtrate was extracted with EtOAc (50 ml x 2) and washed with water and brine. The combined organic layers were concentrated under reduced pressure to remove the solvent after removing water with anhydrous magnesium sulfate. The mixture was purified by column chromatography (hexane:EtOAc = 9:1) to give intermediate 2 (1.96 g, 11.19 mmol, 85%) as a light yellow solid in 85% yield.
[0150] 2) Synthesis of methyl 2-(bromomethyl)-4-cyanobenzoate (Intermediate 3)
[0151] Dissolve intermediate 2 (1.96g, 11.19mmol) in DCE (30ml), add N-bromosuccinimide (2.64g, 22.38mmol) and benzoyl peroxide (0.271g, 1.119mmol), and heat under reflux for 8 hours. After the reaction is complete, cool to room temperature. Concentrate the mixture under reduced pressure to remove the solvent, and purify by column chromatography (hexane: EtOAc = 9:1) to obtain intermediate 3 (2.29g, 9.03mmol, 81%) as a yellow solid in 81% yield.
[0152] 3) Synthesis of 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbonitrile (Intermediate 4)
[0153] Dissolve intermediate 3 (7.34g, 28.9mmol) in DMF (50ml), add 3-aminopiperidine-2,6-dione hydrochloride (4.75g, 28.9mmol) and TEA (12.07ml, 87mmol) at room temperature, and stir at 80℃ overnight. After the reaction is completed, cool to room temperature and concentrate under reduced pressure to remove the solvent. Add water to the mixture, filter the resulting solid, and wash with excess water. Remove water from the solid under reduced pressure to obtain intermediate 4 (6.28g, 23.32mmol, 81%) as a dark blue solid in 81% yield.
[0154] 4) Synthesis of 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Intermediate 5)
[0155] Intermediate 4 (1.7 g, 6.31 mmol) was dissolved in DMA (20 ml), 10% Pd / C (2.32 g, 6.31 mmol) and methanesulfonic acid (0.451 ml, 6.94 mmol) were added, and the mixture was stirred overnight at 40° C. under hydrogen gas. After the reaction was completed, the mixture was cooled to 40° C. and cooled to 5° C. (R) The mixture was filtered with 50 ml of DMA and washed with 50 ml of DMA. The filtrate was concentrated under reduced pressure and the mixture was precipitated with a mixture of methanol / ethyl ether (5 ml / 30 ml). The precipitate was filtered to give intermediate 5 (0.99 g, 2.69 mmol, 43%) as a grey solid in 43% yield.
[0156] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.27 (s, 3H), 7.79 (d, J = 7.8 Hz, 1H), 7.70 (s, 1H), 7.60 (d, J = 7.9 Hz, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.49 (d, J = 17.4 Hz, 1H), 4.35 (d, J = 17.4 Hz, 1H), 4.17 (q, J = 5.9 Hz, 2H), 2.97-2.87 (m, 1H), 2.60 (d, J = 17.4 Hz, 1H), 2.45-2.38 (m, 1H), 2.34 (s, 6H), 2.06-1.97 (m, 1H).
[0157] In addition, Reaction Scheme 2 can be prepared by the method disclosed in Korean Patent Publication No. 10-2011-0019761.
[0158] The method for producing the compound represented by Chemical Formula 1 according to the present invention disclosed in the above preparation method should be understood as an example of a method for producing the compound of the present invention, and any method capable of producing the compound represented by Chemical Formula 1 produced by the present invention is included in the present invention. In addition, the method presented in the specification of the present invention and preparation methods that a skilled artisan can easily try by modifying and altering the method should be understood to be included in the scope of the present invention, and it can be understood that this is obvious to a skilled artisan in the field.
[0159] As used herein, the following terms have the following meanings unless otherwise specified: Any term not defined has its art-understood meaning.
[0160] As used herein, "halogen" or "halo" refers to fluoro (F), chlorine (Cl), bromine (Br), or iodo (I).
[0161] As used herein, the term "alkyl" refers to a single bonded straight or branched chain hydrocarbon radical, including but not limited to methyl, ethyl, propyl, and the like.
[0162] The term "alkoxy" as used herein means a single bonded straight or branched chain saturated hydrocarbon attached oxygen radical, including but not limited to methoxy, ethoxy, propoxy, and the like.
[0163] The term "halogenalkyl" as used herein refers to a substituted alkyl group as described above, where one or more hydrogen atoms on the alkyl group have been replaced with a halogen group, including, but not limited to, trifluoromethyl, difluoromethyl, trifluoroethyl, etc.
[0164] The term "halogenalkoxy" as used herein refers to the group alkyl-O-, where one or more of the hydrogen atoms on the alkyl group is replaced with a halogen group, including, but not limited to, trifluoromethoxy.
[0165] The term "heterocycloalkyl" refers to a cyclic, single-bonded, saturated hydrocarbon group containing one or more heteroatoms such as N, O, or S, and includes, but is not limited to, piperidinyl, morpholinyl, tetrahydrofuranyl, piperazinyl, etc., depending on the number and type of heteroatoms contained in the ring and the number of carbon atoms.
[0166] The term "heteroaryl" refers to an aromatic ring compound containing one or more heteroatoms such as N, O, or S, and includes, but is not limited to, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, indazolyl, benzimidazolyl, benzoisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, naphthofuranyl, quinolinyl, isoquinolinyl, quinoxalinyl, etc., depending on the number and type of heteroatoms contained in the ring and the number of carbon atoms.
[0167] The compounds of formula 1 of the present invention may include any salts, hydrates, solvates and prodrugs that can be prepared by conventional methods, in addition to pharmaceutically acceptable salts. The compounds of the present invention may also contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All such compounds and partial stereoisomers are within the scope of the present invention.
[0168] As used herein, the pharma- ceutically acceptable salt refers to a salt or complex of Formula 1 that possesses the desired biological activity. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), as well as salts formed with acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid. The compounds may also be administered as pharma- ceutically acceptable quaternary salts known to those skilled in the art, including, among others, chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (e.g., benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamoate, mandelloate, and diphenylacetate).
[0169] The acid addition salt according to the present invention can be prepared by a conventional method. For example, the derivative of Chemical Formula 1 can be dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane, acetonitrile, etc., and an organic or inorganic acid can be added thereto, and the precipitate formed can be filtered and dried to prepare the acid addition salt. Alternatively, the acid addition salt can be prepared by distilling the solvent and an excess amount of acid under reduced pressure, drying the resulting precipitate, and then crystallizing the resulting precipitate in an organic solvent.
[0170] Pharmaceutically acceptable metal salts can also be prepared using bases. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving the compound in a solution of an excess of alkali metal hydroxide or alkaline earth metal hydroxide, filtering the undissolved compound salt, and evaporating and drying the filtrate. In this case, it is pharma- ceutical suitable to prepare sodium, potassium, or calcium salts as metal salts. The corresponding salts can also be obtained by reacting alkali metal or alkaline earth metal salts with a suitable silver salt (e.g., silver nitrate).
[0171] The present invention also relates to a pharmaceutical composition for preventing or treating leprosy, chronic graft-versus-host disease, inflammatory diseases, or cancer, comprising the compound represented by the above formula 1 or a pharma- ceutically acceptable salt thereof as an active ingredient.
[0172] According to a test example of the present invention, it was confirmed that the CRBN (celebron) protein binds to the CRBN protein and degrades Ikaros / Aiolos and GSPT1. The CRBN protein is a type of E3 ubiquitin ligase, and is known to have the activity of binding to thalidomide and its analogs, pomalidomide and lenalidomide, and attaching ubiquitin to substrate proteins, such as Ikaros / Aiolos and GSPT1.
[0173] The cancer may be selected from the group consisting of breast cancer, colon cancer, lung cancer, small cell carcinoma, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, colon cancer, breast cancer, trumpeteran carcinoma, endometrial carcinoma, cervical cancer, vaginal cancer, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma, but is not limited thereto.
[0174] The pharmaceutical composition according to the present invention may be formulated in an appropriate form together with a commonly used pharma- ceutically acceptable carrier. The term "pharma-ceutically acceptable composition" refers to a composition that is physiologically acceptable and does not usually cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions when administered to humans. In addition, the compositions may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions by a conventional method.
[0175] The carrier, excipient and diluent that can be included in the composition may include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl paraoxybenzoate, propyl paraoxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, it is prepared using a diluent or excipient that is commonly used, such as a filler, stabilizer, binder, disintegrant, or surfactant. The solid preparation for oral administration includes tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing the compound of the present invention with at least one excipient, such as starch, microcrystalline cellulose, sucrose or lactose, low-substituted hydroxypropyl cellulose, hypromellose, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, internal liquids, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavorings, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspension solvents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, tween 61, cacao butter, lauric butter, glycerol, gelatin, etc. In order to prepare a dosage form for parenteral administration, the compound of the above-mentioned formula 1 or a pharma- ceutically acceptable salt thereof is sterilized and / or mixed with auxiliary agents such as preservatives, stabilizers, hydrating agents or emulsifying agents, salts for adjusting osmotic pressure and / or buffers, and other therapeutically useful substances in water to prepare a solution or suspension, which can be prepared into a unit-dosage form in ampoules or vials.
[0176] The pharmaceutical composition includes the compound of Formula 1 and an excipient. The compound may be added in an amount of preferably 0.001% to 50% by weight, more preferably 0.001% to 40% by weight, and most preferably 0.001% to 30% by weight, based on the total weight of the entire composition.
[0177] The pharmaceutical composition containing the compound of formula 1 disclosed in the present invention as an active ingredient may be administered to mammals such as rodents, livestock, and humans by various routes. Any manner of administration may be envisaged, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine, intradural or intracerebrovascular injection. The dosage may vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the administration time, the administration route, the absorption, distribution and excretion rate of the drug, the type of other drugs used, and the prescriber's judgment. Determination of the dosage based on such factors is within the level of one of ordinary skill in the art, and generally, the dosage ranges from 0.01 mg / kg / day to 2000 mg / kg / day. More preferably, the dosage is from 1 mg / kg / day to 500 mg / kg / day. The dosage may be administered once a day or in several divided doses. The dosage is not intended to limit the scope of the present invention in any way. Effect of the Invention
[0178] The compound of formula 1 according to the present invention specifically binds to CRBN protein and participates in its function. Therefore, the compound of the present invention can be useful for preventing or treating leprosy, chronic graft-versus-host disease, inflammatory diseases, or cancers caused by the action of CRBN protein. [Brief description of the drawings]
[0179] [Figure 1] The degradation activity of GSPT1, IKZF1, and GAPDH after treatment with compound 10 of the present invention for 6 hours was measured. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0180] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, this description is provided so that this disclosure will be thorough and complete, and will fully convey the concept of the present invention to those skilled in the art.
[0181] <Example 1. Synthesis of isoindolinone derivative compounds having glutarimide nucleus and confirmation of physicochemical properties>
[0182] Compounds 1 to 86 of the present invention were prepared according to the method disclosed in Korean Patent Publication No. 10-2011-0019761, and their physicochemical properties are as follows.
[0183] Compound 1. 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide
[0184] TIFF2024544507000005.tif96166
[0185] 3-(5-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione methanesulfonate (15 mg, 0.00406 mmol) was dissolved in DMF (1 ml), and 6-chloro-1H-indazole-3-carboxylic acid (9.5 mg, 0.0487 mmol), EDCl·HCl (8.5 mg, 0.0446 mmol), HOBt·HO (6.0 mg, 0.0446 mmol), and DIPEA (28 μl, 0.162 mmol) were added, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, and the residue was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and separated and purified using column chromatography to obtain the target compound 1 (5.0 mg, 28%) as a white solid.
[0186] 1H NMR (500 MHz, DMSO-d6) δ 13.76 (s, 1H), 10.98 (s, 1H), 9.18 (t, J = 6.3 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 8.7, 1.8 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.60 (d, J = 6.3 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.63 - 2.57 (m, 1H), 2.41 - 2.32 (m, 1H), 2.03 - 1.94 (m, 2H).
[0187] Compound 2. 3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide
[0188] TIFF2024544507000006.tif32166
[0189] Compound 2 was synthesized in the same manner as compound 1, except that 3-(4-chlorophenyl)-1H-pyrazole-5-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0190] 1H NMR (500 MHz, DMSO-d6) δ 13.75 (s, 1H), 10.98 (s, 1H), 8.99 (s, 1H), 7.82 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 7.8 Hz, 1H), 7.53 (m, 3H), 7.47 (d, J = 7.9 Hz, 1H), 7.20 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.61 (m, 1H), 2.38 (m, 1H), 2.05 - 1.94 (m, 1H).
[0191] Compound 3. 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide
[0192] TIFF2024544507000007.tif32166
[0193] Compound 3 was synthesized in the same manner as compound 1, except that 5-chloro-1H-benzo[d]imidazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0194] 1H NMR (500 MHz, DMSO-d6) δ 13.46 (s, 1H), 10.98 (s, 1H), 9.71 (t, J = 6.4 Hz, 1H), 7.79 - 7.54 (m, 4H), 7.49 (d, J = 7.9 Hz, 1H), 7.33 (dd, J = 8.7, 2.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.65 - 2.55 (m, 1H), 2.37 (m, 1H), 1.99 (m, 1H).
[0195] Compound 4. 5,6-dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide
[0196] TIFF2024544507000008.tif39166
[0197] Compound 4 was synthesized in the same manner as compound 1, except that 5,6-dichloro-1H-indazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0198] 1H NMR (500 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.25 (t, J = 6.3 Hz, 1H), 8.32 (s, 1H), 7.99 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.60 (d, J = 6.3 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.59 (m, 1H), 2.37 (m, 1H), 2.03 - 1.97 (m, 1H).
[0199] Compound 5. 3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide
[0200] TIFF2024544507000009.tif32166
[0201] Compound 5 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0202] 1H NMR (500 MHz, DMSO-d6) δ 13.80 (s, 1H), 10.98 (s, 1H), 9.01 (s, 1H), 7.87 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.54 (s, 1H), 7.51 - 7.45 (m, 2H), 7.42 (d, J = 9.1 Hz, 1H), 7.26 (s, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.58 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.65 - 2.55 (m, 1H), 2.38 (m, 1H), 2.04 - 1.96 (m, 1H).
[0203] Compound 6. 6-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide
[0204] TIFF2024544507000010.tif32166
[0205] Compound 6 was synthesized in the same manner as compound 1, except that 6-chloro-1H-indole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0206] 1H NMR (400 MHz, DMSO-d6) δ 11.69 (s, 1H), 10.97 (s, 1H), 8.62 (t, J = 6.0 Hz, 1H), 8.18 - 8.08 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.51 - 7.46 (m, 2H), 7.12 (dd, J = 8.6, 2.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.88 (m, 1H), 2.68 - 2.55 (m, 1H), 2.42 - 2.29 (m, 1H), 2.02 - 1.90 (m, 1H).
[0207] Compound 7. 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide
[0208] TIFF2024544507000011.tif39166
[0209] Compound 7 was synthesized in the same manner as compound 1, except that 5-chloro-1H-indole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0210] 1H NMR (500 MHz, DMSO-d6) δ 11.78 (s, 1H), 10.98 (s, 1H), 8.64 (t, J = 6.0 Hz, 1H), 8.18 - 8.12 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.47 (dd, J = 11.4, 8.4 Hz, 2H), 7.17 (dd, J = 8.6, 2.2 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 5.9 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.61 (m, 1H), 2.37 (m, 1H), 2.03 - 1.96 (m, 1H).
[0211] Compound 8. 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide
[0212] TIFF2024544507000012.tif39166
[0213] Compound 8 was synthesized in the same manner as compound 1, except that 5-chloro-1H-indazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0214] 1H NMR (500 MHz, DMSO-d6) δ 13.85 (s, 1H), 10.98 (s, 1H), 9.19 (t, J = 6.3 Hz, 1H), 8.15 (d, J = 2.0 Hz, 1H), 7.68 (dd, J = 8.4, 5.0 Hz, 2H), 7.56 (s, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.44 (dd, J = 8.9, 2.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.61 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.59 (m, 1H), 2.37 (m, 1H), 1.99 (m, 1H).
[0215] Compound 9. 6-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-2-carboxamide
[0216] TIFF2024544507000013.tif32166
[0217] Compound 9 was synthesized in the same manner as compound 1, except that 6-chloro-1H-indole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0218] 1H NMR (500 MHz, DMSO-d6) δ 11.78 (s, 1H), 10.98 (s, 1H), 9.22 (t, J = 6.1 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.56 (s, 1H), 7.51 - 7.47 (m, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.22 (s, 1H), 7.06 (dd, J = 8.6, 2.0 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.63 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.62 - 2.55 (m, 1H), 2.37 (m, 1H), 2.06 - 1.93 (m, 1H).
[0219] Compound 10. 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]isoxazole-3-carboxamide
[0220] TIFF2024544507000014.tif32166
[0221] Compound 10 was synthesized in the same manner as compound 1, except that 5-chlorobenzo[d]isoxazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0222] 1H NMR (500 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.80 (t, J = 6.2 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.57 (dd, J = 8.5, 1.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.64 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.96 - 2.89 (m, 1H), 2.61 (m, 1H), 2.38 (dd, J = 13.1, 4.4 Hz, 1H), 1.99 (m, 1H).
[0223] Compound 11. 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide
[0224] TIFF2024544507000015.tif32166
[0225] Compound 11 was synthesized in the same manner as compound 1, except that 5-(4-chlorophenyl)isoxazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0226] 1H NMR (500 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.53 (t, J = 6.2 Hz, 1H), 8.00 - 7.94 (m, 2H), 7.71 (d, J = 7.9 Hz, 1H), 7.67 - 7.62 (m, 2H), 7.56 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.46 (s, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.61 (m, 1H), 2.38 (m, 1H), 1.99 (m, 1H).
[0227] Compound 12. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide
[0228] TIFF2024544507000016.tif32166
[0229] Compound 12 was synthesized in the same manner as compound 1, except that 4-phenylpicolinic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0230] 1H NMR (500 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.57 (t, J = 6.4 Hz, 1H), 8.73 (d, J = 5.1 Hz, 1H), 8.34 - 8.25 (m, 1H), 7.96 (dd, J = 5.1, 1.9 Hz, 1H), 7.86 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.59 - 7.47 (m, 5H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.64 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.61 (m, 1H), 2.37 (m, 1H), 2.08 - 1.93 (m, 1H).
[0231] Compound 13. 3-(3,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide
[0232] TIFF2024544507000017.tif32166
[0233] Compound 13 was synthesized in the same manner as compound 1, except that 3-(3,4-dichlorophenyl)-1H-pyrazole-5-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0234] 1H NMR (400 MHz, DMSO-d6) δ 13.85 (m, 1H), 10.98 (s, 1H), 9.05 (m, 1H), 8.05 (m, 1H), 7.88 - 7.66 (m, 3H), 7.61 - 7.44 (m, 2H), 7.31 (m, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.58 (d, J = 14.5 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.59 (d, J = 17.0 Hz, 1H), 2.38 (m, 1H), 2.05 - 1.92 (m, 1H).
[0235] Compound 14. 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrrole-2-carboxamide
[0236] TIFF2024544507000018.tif32166
[0237] Compound 14 was synthesized in the same manner as compound 1, except that 4-(3-chlorophenyl)-1H-pyrrole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0238] 1H NMR (400 MHz, DMSO-d6) δ 11.80 (s, 1H), 10.98 (s, 1H), 8.82 - 8.65 (m, 1H), 7.70 (dd, J = 7.9, 2.7 Hz, 1H), 7.62 - 7.45 (m, 6H), 7.35 (m, 1H), 7.28 (s, 1H), 7.22 - 7.13 (m, 1H), 5.11 (dd, J = 13.3, 4.9 Hz, 1H), 4.57 (d, J = 5.8 Hz, 2H), 4.45 (d, J = 17.5 Hz, 1H), 4.31 (d, J = 17.0 Hz, 1H), 2.98 - 2.84 (m, 1H), 2.63 (m,1H), 2.40 - 2.32 (m, 1H), 2.04 - 1.96 (m, 1H).
[0239] Compound 15. 1-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-1,2,3-triazole-4-carboxamide
[0240] TIFF2024544507000019.tif32166
[0241] Compound 15 was synthesized in the same manner as compound 1, except that 1-(3-chlorophenyl)-1H-1,2,3-triazole-4-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0242] 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.42 (t, J = 6.3 Hz, 1H), 9.39 (s, 1H), 8.13 (t, J = 2.0 Hz, 1H), 7.99 (dt, J = 8.0, 1.6 Hz, 1H), 7.78 - 7.58 (m, 3H), 7.56 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.61 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.66 - 2.57 (m, 1H), 2.42 - 2.29 (m, 1H), 2.05 - 1.93 (m, 1H).
[0243] Compound 16. 5,6-dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide
[0244] TIFF2024544507000020.tif32166
[0245] Compound 16 was synthesized in the same manner as compound 1, except that 5,6-dichloro-1H-benzo[d]imidazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0246] 1H NMR (400 MHz, DMSO-d6) δ 13.62 (s, 1H), 10.99 (s, 1H), 9.78 (t, J = 6.3 Hz, 1H), 8.03 (s, 1H), 7.75 (s, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.49 (dd, J = 7.9, 1.4 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.61 (d, J = 6.3 Hz, 2H), 4.44 (d, J = 17.4 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.95 - 2.86 (m, 1H), 2.63 - 2.55 (m, 1H), 2.43 - 2.29 (m, 1H), 2.04 - 1.95 (m, 1H).
[0247] Compound 17. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide
[0248] TIFF2024544507000021.tif32166
[0249] Compound 17 was synthesized in the same manner as compound 1, except that 5-phenyl-4-methyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0250] 1H NMR (400 MHz, DMSO-d6) δ 13.37 (s, 1H), 10.97 (s, 1H), 8.77 (t, J = 6.4 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.61 - 7.39 (m, 7H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.56 (d, J = 6.0 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.96 - 2.85 (m, 1H), 2.66 - 2.57 (m, 1H), 2.36 (m, 4H), 2.01 (m, 1H).
[0251] Compound 18. 4-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide
[0252] TIFF2024544507000022.tif32166
[0253] Compound 18 was synthesized in the same manner as compound 1, except that 4-(4-chlorophenyl)picolinic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0254] 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.58 (t, J = 6.4 Hz, 1H), 8.75 (d, J = 5.1 Hz, 1H), 8.31 (d, J = 1.9 Hz, 1H), 7.97 (dd, J = 5.1, 1.9 Hz, 1H), 7.94 - 7.89 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.65 - 7.61 (m, 2H), 7.56 (s, 1H), 7.54 - 7.46 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.64 (d, J = 6.2 Hz, 2H), 4.44 (d, J = 17.4 Hz, 1H), 4.30 (d, J = 17.4 Hz, 1H), 3.00 - 2.84 (m, 1H), 2.64 - 2.52 (m, 1H), 2.43 - 2.30 (m, 1H) 2.05 - 1.92 (m, 1H).
[0255] Compound 19. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide
[0256] TIFF2024544507000023.tif32166
[0257] Compound 19 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)isoxazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0258] 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.55 (t, J = 6.2 Hz, 1H), 8.05 (d, J = 2.1 Hz, 1H), 7.92 (dt, J = 6.6, 1.9 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.64 - 7.59 (m, 2H), 7.56 (s, 1H), 7.54 (s, 1H), 7.49 (d, J = 7.7 Hz, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 6.2 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.2 Hz, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.42 - 2.33 (m, 1H), 2.05 - 1.94 (m, 1H).
[0259] Compound 20. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)pyrimidine-2-carboxamide
[0260] TIFF2024544507000024.tif39166
[0261] Compound 20 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)pyrimidine-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0262] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.58 (t, J = 6.4 Hz, 1H), 8.76 (d, J = 5.1 Hz, 1H), 8.32 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 5.1, 2.0 Hz, 1H), 7.84 (m, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.64 - 7.54 (m, 3H), 7.50 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.65 (d, J = 6.3 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.90 (m, 1H), 2.64 - 2.55 (m, 1H), 2.44 - 2.30 (m, 1H), 2.00 (m, 1H).
[0263] Compound 21. 1-benzyl-5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide
[0264] TIFF2024544507000025.tif39166
[0265] Compound 21 was synthesized in the same manner as compound 1, except that 1-benzyl-5-(3-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0266] 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.86 (s, 1H), 7.43 (m, 5H), 7.18 - 6.88 (m, 4H), 5.19 (s, 2H), 4.72 (s, 2H), 4.41 (m, 2H), 2.89 (m, 2H), 2.26 (m, 4H), 1.63 (m, 1H), 1.35 - 1.19 (m, 1H).
[0267] Compound 22. 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide
[0268] TIFF2024544507000026.tif39166
[0269] Compound 22 was synthesized in the same manner as compound 1, using 4-(3-chlorophenyl)picolinic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0270] 1 H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.58 (t, J = 6.4 Hz, 1H), 8.76 (d, J = 5.1 Hz, 1H), 8.32 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 5.1, 2.0 Hz, 1H), 7.84 (m, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.64 - 7.54 (m, 3H), 7.50 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.65 (d, J = 6.3 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.90 (m, 1H), 2.64 - 2.55 (m, 1H), 2.44 - 2.30 (m, 1H), 2.00 (m, 1H).
[0271] Compound 23. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-5-phenyl-1H-pyrazole-3-carboxamide
[0272] TIFF2024544507000027.tif32166
[0273] Compound 23 was synthesized in the same manner as compound 1, except that 1-methyl-5-phenyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0274] 1 H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.88 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.60 - 7.55 (m, 3H), 7.54 - 7.45 (m, 4H), 6.80 (s, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.55 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.92 (s, 3jH), 2.98 - 2.82 (m, 1H), 2.64 - 2.54 (m, 1H), 2.44 - 2.32 (m, 1H), 2.00 (m, 1H).
[0275] Compound 24. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-3-phenyl-1H-pyrazole-5-carboxamide
[0276] TIFF2024544507000028.tif32166
[0277] Compound 24 was synthesized in the same manner as compound 1, except that 1-methyl-3-phenyl-1H-pyrazole-5-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0278] 1 H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.20 (t, J = 6.0 Hz, 1H), 7.80 - 7.75 (m, 2H), 7.72 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.44 (m, 2H), 7.37 - 7.29 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 5.9 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.33 (d, J = 17.3 Hz, 1H), 4.12 (s, 3H), 2.97 - 2.86 (m, 1H), 2.65 - 2.56 (m, 1H), 2.37 (m, 1H), 2.06 - 1.97 (m, 1H).
[0279] Compound 25. 5-(2,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide
[0280] TIFF2024544507000029.tif32166
[0281] Compound 25 was synthesized in the same manner as compound 1, except that 5-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0282] 1H NMR (400 MHz, DMSO) δ 13.85 (s, 1H), 10.98 (s, 1H), 9.12 (s, 1H), 7.87 - 7.66 (m, 3H), 7.64 - 7.35 (m, 4H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 (d, J = 5.8 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.91 (m,1H), 2.63 - 2.56 (m, 1H), 2.42 - 2.31 (m, 1H), 2.04 - 1.96 (m, 1H).
[0283] Compound 26. 6-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]thiazole-2-carboxamide
[0284] TIFF2024544507000030.tif32166
[0285] Compound 26 was synthesized in the same manner as compound 1, except that 6-chlorobenzo[d]thiazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0286] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.90 (t, J = 6.3 Hz, 1H), 8.42 (d, J = 2.2 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.75 - 7.66 (m, 2H), 7.59 (s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.93 - 2.85 (m, 1H), 2.60 (m, 1H), 2.40 - 2.32 (m, 1H), 2.03 - 1.95 (m, 1H).
[0287] Compound 27. 4-Bromo-3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide
[0288] TIFF2024544507000031.tif32166
[0289] Compound 27 was synthesized in the same manner as compound 1, except that 4-bromo-3-(3-chlorophenyl)-1H-pyrazole-5-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0290] 1H NMR (400 MHz, DMSO-d6) δ 14.11 (s, 1H), 10.99 (s, 1H), 8.99 (m, 1H), 7.81 (s, 1H), 7.74 (d, J = 7.0 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.62 - 7.55 (m, 3H), 7.49 (d, J = 7.8 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.56 (d, J = 6.1 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.60 (m, 1H), 2.44 - 2.31 (m, 1H), 2.00 (m, 1H).
[0291] Compound 28. 5-(2,5-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide
[0292] TIFF2024544507000032.tif32166
[0293] Compound 28 was synthesized in the same manner as compound 1, except that 5-(2,5-dichlorophenyl)-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0294] 1H NMR (400 MHz, DMSO-d6) δ 14.03 (s, 0.5H), 13.75 (s, 0.4H), 10.99 (s, 1H), 9.27 (s, 0.5H), 8.99 (s, 0.5H), 7.89 - 7.42 (m, 7H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.60 (m, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.64 - 2.56 (m, 1H), 2.43 - 2.29 (m, 1H), 2.05 - 1.95 (m, 1H).
[0295] Compound 29. 5-(2,4-dimethylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide
[0296] TIFF2024544507000033.tif32166
[0297] Compound 29 was synthesized in the same manner as compound 1, except that 5-(2,4-dimethylphenyl)-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0298] 1H NMR (500 MHz, DMSO-d6) δ 13.40 (s, 1H), 11.00 (s, 1H), 8.92 (s, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.37 (s, 1H), 7.20 - 7.05 (m, 2H), 6.78 (s, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.58 (d, J = 6.0 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.65 - 2.56 (m, 1H), 2.43 - 2.35 (m, 4H), 2.32 (s, 3H), 2.03 - 1.96 (m, 1H).
[0299] Compound 30. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-3-carboxamide
[0300] TIFF2024544507000034.tif32166
[0301] Compound 30 was synthesized in the same manner as compound 1, except that [1,1'-biphenyl]-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0302] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.30 (t, J = 6.0 Hz, 1H), 8.21 (t, J = 1.8 Hz, 1H), 7.91 (dt, J = 7.8, 1.3 Hz, 1H), 7.86 (m, 1H), 7.78 - 7.74 (m, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.62 - 7.57 (m, 2H), 7.51 (m, 3H), 7.45 - 7.36 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.64 (d, J = 5.9 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.60 (m, 1H), 2.45 - 2.34 (m, 1H), 2.03 - 1.95 (m, 1H).
[0303] Compound 31. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methylpicolinamide
[0304] TIFF2024544507000035.tif32166
[0305] Compound 31 was synthesized in the same manner as compound 1, except that 4-methylpicolinic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0306] 1H NMR (500 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.46 (t, J = 6.4 Hz, 1H), 8.54 - 8.50 (m, 1H), 7.91 (dd, J = 1.8, 0.9 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.50 - 7.43 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.61 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.2 Hz, 1H), 2.96 - 2.87 (m, 1H), 2.63 - 2.57 (m, 1H), 2.42 (s, 3H), 2.40 - 2.35 (m, 1H), 1.99 (m, 1H).
[0307] Compound 32. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide
[0308] TIFF2024544507000036.tif32166
[0309] Compound 32 was synthesized in the same manner as compound 1, using 4-phenylpicolinic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0310] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.46 (t, J = 5.9 Hz, 1H), 9.06 (dd, J = 4.7, 2.1 Hz, 2H), 8.54 (t, J = 2.2 Hz, 1H), 7.85 - 7.80 (m, 2H), 7.72 (d, J = 7.7 Hz, 1H), 7.60 (s, 1H), 7.57 - 7.51 (m, 3H), 7.49 - 7.45 (m, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.67 (d, J = 5.9 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.98 - 2.85 (m, 1H), 2.66 - 2.57 (m, 1H), 2.44 - 2.35 (m, 1H), 2.01 (m, 1H).
[0311] Compound 33. 6-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]oxazole-2-carboxamide
[0312] TIFF2024544507000037.tif32166
[0313] Compound 33 was synthesized in the same manner as compound 1, except that 5-chlorobenzo[d]oxazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0314] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 10.01 (t, J = 6.3 Hz, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.94 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.61 - 7.56 (m, 2H), 7.54 - 7.48 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.65 - 2.56 (m, 1H), 2.38 (m, 1H), 2.04 - 1.96 (m, 1H).
[0315] Compound 34. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide
[0316] TIFF2024544507000038.tif32166
[0317] Compound 34 was synthesized in the same manner as compound 1, except that 1H-indazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0318] 1H NMR (500 MHz, DMSO-d6) δ 13.64 (s, 1H), 10.99 (s, 1H), 9.13 (t, J = 6.3 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.63 (dd, J = 8.4, 1.0 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.43 (m, 1H), 7.25 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 1.99 (m, 1H).
[0319] Compound 35. 3-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrazole-5-carboxamide
[0320] TIFF2024544507000039.tif32166
[0321] Compound 35 was synthesized in the same manner as compound 1, except that 5-bromo-1-methyl-1H-imidazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0322] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.22 (t, J = 6.0 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.49 - 7.44 (m, 1H), 7.04 (s, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.56 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 4.05 (s, 3H), 2.97 - 2.86 (m, 1H), 2.66 - 2.57 (m, 1H), 2.42 - 2.33 (m, 1H), 2.03 - 1.96 (m, 1H).
[0323] Compound 36. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-indazole-3-carboxamide
[0324] TIFF2024544507000040.tif32166
[0325] Compound 36 was synthesized in the same manner as compound 1, except that 1-methyl-1H-indazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0326] 1H NMR (500 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.09 (t, J = 6.3 Hz, 1H), 8.18 (m, 1H), 7.75 (dd, J = 8.5, 0.9 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.57 (s, 1H), 7.53 - 7.43 (m, 2H), 7.28 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.61 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 4.16 (s, 3H), 2.98 - 2.85 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 2.05 - 1.96 (m, 1H).
[0327] Compound 37. 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-imidazole-2-carboxamide
[0328] TIFF2024544507000041.tif32166
[0329] Compound 37 was synthesized in the same manner as compound 1, except that 1-methyl-1H-indazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0330] 1H NMR (500 MHz, MeOD) δ 7.79 - 7.75 (m, 1H), 7.56 (m, 1H), 7.53 - 7.48 (m, 1H), 7.28 (s, 1H), 5.14 (dd, J = 13.4, 5.2 Hz, 1H), 4.63 (s, 2H), 4.50 (d, J = 17.0 Hz, 1H), 4.44 (d, J = 17.1 Hz, 1H), 3.99 (s, 3H), 2.95 - 2.85 (m, 1H), 2.77 (m, 1H), 2.48 (m, 1H), 2.21 - 2.12 (m, 1H).
[0331] Compound 38. 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide
[0332] TIFF2024544507000042.tif32166
[0333] Compound 38 was synthesized in the same manner as compound 1, except that 4-bromo-1-methyl-1H-pyrrole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0334] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.75 (t, J = 6.1 Hz, 1H), 7.69 (dd, J = 7.9, 0.7 Hz, 1H), 7.51 (d, J = 1.4 Hz, 1H), 7.47 - 7.42 (m, 1H), 7.13 (d, J = 1.9 Hz, 1H), 6.94 (d, J = 1.9 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.50 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.83 (s, 3H), 2.96 - 2.87 (m, 1H), 2.65 - 2.56 (m, 1H), 2.44 - 2.35 (m, 1H), 2.00 (m, 1H).
[0335] Compound 39. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-4-phenyl-1H-pyrrole-2-carboxamide
[0336] TIFF2024544507000043.tif32166
[0337] Compound 39 was synthesized in the same manner as compound 1, except that 1-methyl-4-phenyl-1H-pyrrole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0338] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.76 (t, J = 6.1 Hz, 1H), 7.72 - 7.69 (m, 1H), 7.55 (s, 1H), 7.53 - 7.50 (m, 2H), 7.48 (d, J = 7.7 Hz, 0H), 7.44 (d, J = 1.9 Hz, 1H), 7.38 - 7.33 (m, 1H), 7.28 (d, J = 2.0 Hz, 1H), 7.19 - 7.14 (m, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.4 Hz, 1H), 3.89 (s, 3H), 2.90 (m, 1H), 2.66 - 2.56 (m, 1H), 2.44 - 2.33 (m, 1H), 2.04 - 1.97 (m, 1H).
[0339] Compound 40. 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide
[0340] TIFF2024544507000044.tif32166
[0341] Compound 40 was synthesized in the same manner as compound 1, except that 4-(3-chlorophenyl)-1-methyl-1H-pyrrole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0342] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.74 (t, J = 6.1 Hz, 1H), 7.71 (dd, J = 7.8, 0.7 Hz, 1H), 7.56 (m, 3H), 7.51 - 7.45 (m, 2H), 7.38 (t, J = 7.8 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.21 (m, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 3.88 (s, 3H), 2.98 - 2.84 (m, 1H), 2.65 - 2.58 (m, 1H), 2.44 - 2.35 (m, 1H), 2.00 (m, 1H).
[0343] Compound 41. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide
[0344] TIFF2024544507000045.tif39166
[0345] Compound 41 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0346] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.73 (t, J = 6.3 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.62 - 7.46 (m, 5H), 7.38 (m, 1H), 5.12 (dd, J = 13.2, 5.1 Hz, 1H), 4.54 (d, J = 6.3 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 3.86 (d, J = 7.3 Hz, 2H), 2.92 (m, 1H), 2.62 (m, 1H), 2.39 (m, 1H), 2.11 (s, 3H), 2.06 - 1.97 (m, 3fH), 0.71 (d, J = 6.7 Hz, 6H).
[0347] Compound 42. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide
[0348] TIFF2024544507000046.tif39166
[0349] Compound 42 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0350] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.96 (t, J = 6.3 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.50 - 7.26 (m, 9H), 7.19 (dt, J = 7.3, 1.5 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.57 (d, J = 6.3 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.99 - 2.84 (m, 1H), 2.64 - 2.58 (m, 1H), 2.37 (m, 1H), 2.24 (s, 3H), 2.00 (m, 1H).
[0351] Compound 43. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-(4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
[0352] TIFF2024544507000047.tif45166
[0353] Compound 43 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)-1-(4-fluorobenzyl)-4-methyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0354] 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.81 (t, J = 6.3 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.57 - 7.45 (m, 4H), 7.37 (t, J = 2.0 Hz, 1H), 7.27 (dt, J = 7.1, 1.6 Hz, 1H), 7.14 - 7.07 (m, 2H), 7.03 - 6.96 (m, 2H), 5.29 (s, 2H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.54 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.66 - 2.55 (m, 1H), 2.44 - 2.33 (m, 1H), 2.13 (s, 3H), 2.01 (m, 1H).
[0355] Compound 44. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-(4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
[0356] TIFF2024544507000048.tif32166
[0357] Compound 44 was synthesized in the same manner as compound 1, except that 5-chlorobenzo[d]thiazole-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0358] 1H NMR (300 MHz, DMSO) δ 10.99 (s, 1H), 9.93 (t, J = 6.3 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 2.0 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.66 (dd, J = 8.7, 2.1 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 8.1 Hz, 1H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.62 (d, J = 6.2 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.99 - 2.84 (m, 1H), 2.60 (m, 1H), 2.45 - 2.33 (m, 1H), 2.05 - 1.95 (m, 1H).
[0359] Compound 45. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methyl-4-phenylpicolinamide
[0360] TIFF2024544507000049.tif32166
[0361] Compound 45 was synthesized in the same manner as compound 1, using 5-methyl-4-phenylpicolinic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0362] 1H NMR (400 MHz, DMSO) δ 10.98 (s, 1H), 9.50 (t, J = 6.4 Hz, 1H), 8.61 (s, 1H), 7.85 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.58 - 7.42 (m, 7H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.65 - 2.56 (m, 1H), 2.45 - 2.37 (m, 1H), 2.35 (s, 3H), 2.05 - 1.92 (m, 1H).
[0363] Compound 46. 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide
[0364] TIFF2024544507000050.tif32166
[0365] Compound 46 was synthesized in the same manner as compound 1, using 5-chloro-4-phenylpicolinic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0366] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.60 (t, J = 6.4 Hz, 1H), 8.84 (s, 1H), 8.01 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.63 - 7.45 (m, 7H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.63 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.4 Hz, 1H), 2.91 (m, 1H), 2.66 - 2.55 (m, 1H), 2.44 - 2.31 (m, 1H) 2.04 - 1.95 (m, 1H).
[0367] Compound 47. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-phenylpyrazine-2-carboxamide
[0368] TIFF2024544507000051.tif39166
[0369] Compound 47 was synthesized in the same manner as compound 1, except that 6-phenylpyrazine-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0370] 1H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 9.76 (t, J = 6.4 Hz, 1H), 9.51 (s, 1H), 9.15 (s, 1H), 8.46 - 8.39 (m, 2H), 7.71 (d, J = 7.9 Hz, 1H), 7.62 - 7.50 (m, 5H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.70 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 2.03 - 1.95 (m, 1H).
[0371] Compound 48. 3-(2-chloro-6-fluorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methylisoxazole-4-carboxamide
[0372] TIFF2024544507000052.tif39166
[0373] Compound 48 was synthesized in the same manner as compound 1, using 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0374] 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.69 (t, J = 6.0 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.62-7.54 (m, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.40 (s, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.37-7.34 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.44 (d, J = 6.4 Hz, 2H), 4.40 (s, 1H), 4.29 (d, J = 17.3 Hz, 1H), 2.97-2.86 (m, 1H), 2.67 (s, 3H), 2.64-2.57 (m, 1H), 2.47-2.35 (m, 1H), 2.03-1.97 (m, 1H).
[0375] Compound 49. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-phenyl-1H-pyrazole-5-carboxamide
[0376] TIFF2024544507000053.tif39166
[0377] Compound 49 was synthesized in the same manner as compound 1, except that 3-phenyl-1H-pyrazole-5-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0378] 1H NMR (300 MHz, DMSO-d6) δ 13.71 (s, 1H), 10.99 (s, 1H), 8.99 (s, 1H), 7.83-7.75 (m, 2H), 7.70 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.47 (t, J = 7.5 Hz, 3H), 7.37 (t, J = 7.3 Hz, 1H), 7.15 (s, 1H), 5.10 (dd, J = 13.2, 5.1 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.97-2.83 (m, 1H), 2.63 (s, 1H), 2.44-2.26 (m, 1H), 2.05-1.93 (m, 1H).
[0379] Compound 50. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
[0380] TIFF2024544507000054.tif39166
[0381] Compound 50 was synthesized in the same manner as compound 1, using 1-(cyclohexa-1,5-dien-1-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0382] 1H NMR (300 MHz, DMSO) δ 11.00 (s, 1H), 9.23 (t, J = 6.0 Hz, 1H), 8.23 (s, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.63 - 7.46 (m, 7H), 5.12 (dd, J = 13.2, 5.1 Hz, 1H), 4.58 (d, J = 5.9 Hz, 2H), 4.47 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 3.03 - 2.82 (m, 1H), 2.60 (m, 1H), 2.40 (m, 1H), 2.01 (m, 1H).
[0383] Compound 51. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-4-carboxamide
[0384] TIFF2024544507000055.tif32166
[0385] Compound 51 was synthesized in the same manner as compound 1, except that [1,1′-biphenyl]-4-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0386] 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 9.23 (t, J = 6.0 Hz, 1H), 8.04 - 8.00 (m, 2H), 7.83 - 7.79 (m, 2H), 7.77 - 7.73 (m, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.54 - 7.47 (m, 3H), 7.45 - 7.40 (m, 1H), 5.12 (dd, J = 13.4, 5.1 Hz, 1H), 4.63 (d, J = 5.9 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.67 - 2.57 (m, 1H), 2.39 (m, 1H), 2.07 - 1.94 (m, 1H).
[0387] Compound 52. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1'-biphenyl]-2-carboxamide
[0388] TIFF2024544507000056.tif39166
[0389] Compound 52 was synthesized in the same manner as compound 1, except that [1,1'-biphenyl]-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0390] 1H NMR (500 MHz, DMSO-d6) δ 11.01 (s, 1H), 8.74 (t, J = 6.0 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.51 (td, J = 7.4, 1.7 Hz, 1H), 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.45-7.41 (m, 1H), 7.39 (dd, J = 7.6, 1.3 Hz, 1H), 7.36-7.29 (m, 5H), 7.18 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 1H), 4.41-4.34 (m, 3H), 4.26 (d, J = 17.2 Hz, 1H), 2.98-2.87 (m, 1H), 2.64-2.57 (m, 1H), 2.48-2.38 (m, 1H), 2.04-1.97 (m, 1H).
[0391] Compound 53. 1-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)cyclopentane-1-carboxamide
[0392] TIFF2024544507000057.tif45166
[0393] Compound 53 was synthesized in the same manner as compound 1, except that 1-(4-chlorophenyl)cyclopentane-1-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0394] 1H NMR (500 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.21 (t, J = 6.1 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.42-7.34 (m, 4H), 7.17 (d, J = 8.0 Hz, 1H), 7.02 (s, 1H), 5.09 (dd, J = 13.4, 5.1 Hz, 1H), 4.32 (d, J = 17.2 Hz, 1H), 4.28 (d, J = 6.0 Hz, 2H), 4.18 (d, J = 17.2 Hz, 1H), 2.95-2.86 (m, 1H), 2.64-2.54 (m, 3H), 2.43-2.30 (m, 1H), 2.03-1.96 (m, 1H), 1.85-1.77 (m, 2H), 1.67-1.54 (m, 4H).
[0395] Compound 54. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenylcyclopentane-1-carboxamide
[0396] TIFF2024544507000058.tif39166
[0397] Compound 54 was synthesized in the same manner as compound 1, except that 1-phenylcyclopentane-1-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0398] 1H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.40-7.22 (m, 6H), 7.18-7.12 (m, 1H), 7.04 (s, 1H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.32 (d, J = 17.2 Hz, 3H), 4.18 (d, J = 17.3 Hz, 1H), 2.97-2.84 (m, 1H), 2.60 (d, J = 15.9 Hz, 3H), 2.44-2.26 (m, 1H), 2.06-1.92 (m, 1H), 1.91-1.76 (m, 2H), 1.69-1.55 (m, 4H).
[0399] Compound 55. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-1-phenylpyrrolidine-3-carboxamide
[0400] TIFF2024544507000059.tif32166
[0401] Compound 55 was synthesized in the same manner as compound 1, using 2-oxo-1-phenylpyrrolidine-3-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0402] 1H NMR (300 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.84 (t, J = 5.9 Hz, 1H), 7.68 (dd, J = 9.8, 7.9 Hz, 3H), 7.55 (s, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.43-7.36 (m, 2H), 7.20-7.13 (m, 1H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.57-4.38 (m, 3H), 4.31 (dd, J = 17.4, 2.9 Hz, 1H), 3.95-3.81 (m, 2H), 2.97-2.85 (m, 1H), 2.63 (s, 1H), 2.46-2.28 (m, 3H), 2.05-1.95 (m, 1H).
[0403] Compound 56. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzofuran-2-carboxamide
[0404] TIFF2024544507000060.tif32166
[0405] Compound 56 was synthesized in the same manner as compound 1, using benzofuran-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0406] 1H NMR (500 MHz, DMSO) δ 11.00 (s, 1H), 9.44 (t, J = 6.2 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.69 (dd, J = 17.0, 8.2 Hz, 2H), 7.60 (s, 1H), 7.57 (s, 1H), 7.49 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 5.11 (dd, J = 13.3, 4.9 Hz, 1H), 4.61 (d, J = 5.9 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.97 - 2.85 (m, 1H), 2.60 (m, 1H), 2.39 (m, 1H), 2.01 (m, 1H).
[0407] Compound 57. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxy-1H-indole-2-carboxamide
[0408] TIFF2024544507000061.tif32166
[0409] Compound 57 was synthesized in the same manner as compound 1, using 5-methoxy-1H-indole-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0410] 1H NMR (400 MHz, DMSO) δ 11.46 (d, J = 2.2 Hz, 1H), 10.99 (s, 1H), 9.09 (t, J = 6.1 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.9 Hz, 1H), 7.10 (dd, J = 6.2, 2.2 Hz, 2H), 6.84 (dd, J = 8.9, 2.5 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.63 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.76 (s, 3H), 2.91 (m, 1H), 2.65 - 2.58 (m, 1H), 2.38 (m, 1H), 2.00 (m, 1H).
[0411] Compound 58. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[b]thiophene-2-carboxamide
[0412] TIFF2024544507000062.tif32166
[0413] Compound 58 was synthesized in the same manner as compound 1, except that benzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0414] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.43 (t, J = 6.0 Hz, 1H), 8.16 (s, 1H), 8.05 - 8.02 (m, 1H), 7.96 (m, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.58 (s, 1H), 7.53 - 7.40 (m, 3H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.62 (d, J = 5.9 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 2.00 (m, 1H).
[0415] Compound 59. 7-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-hydroxyquinoline-3-carboxamide
[0416] TIFF2024544507000063.tif32166
[0417] Compound 59 was synthesized in the same manner as compound 1, using 7-chloro-4-hydroxyquinoline-3-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0418] 1H NMR (400 MHz, DMSO) δ 12.75 (s, 1H), 10.98 (s, 1H), 10.50 - 10.29 (m, 1H), 8.82 (s, 0.5H), 8.73 (s, 0.5H), 8.25 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 2.1 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.67 - 7.62 (m, 1H), 7.56 (s, 1H), 7.54 - 7.43 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.68 (t, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 3.00 - 2.87 (m, 1H), 2.70 - 2.57 (m, 1H), 2.43 - 2.26 (m, 1H), 2.04 - 1.94 (m, 1H).
[0419] Compound 60. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-2H-chromene-3-carboxamide
[0420] TIFF2024544507000064.tif32166
[0421] Compound 60 was synthesized in the same manner as compound 1, using 2-oxo-2H-chromene-3-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0422] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.26 (t, J = 6.1 Hz, 1H), 8.89 (s, 1H), 8.00 (dd, J = 7.8, 1.6 Hz, 1H), 7.80 - 7.74 (m, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.58 (s, 1H), 7.52 (t, J = 7.9 Hz, 2H),7.45 (t, J = 7.5 Hz, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.67 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.64 - 2.57 (m, 1H), 2.38 (m, 1H), 2.06 - 1.95 (m, 1H).
[0423] Compound 61. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)chromene-4-carboxamide
[0424] TIFF2024544507000065.tif32166
[0425] Compound 61 was synthesized in the same manner as compound 1, using chromene-4-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0426] 1H NMR (400 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.66 (t, J = 5.9 Hz, 1H), 9.53 (s, 1H), 8.58 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.3 Hz, 1H), 8.08 - 8.02 (m, 1H), 8.00 - 7.94 (m, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.67 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 5.13 (dd, J = 13.3, 5.1 Hz, 1H), 4.72 (d, J = 5.9 Hz, 2H), 4.49 (d, J = 17.3 Hz, 1H), 4.36 (d, J = 17.3 Hz, 1H), 2.93 (m, 1H), 2.67 - 2.56 (m, 1H), 2.43 - 2.29 (m, 1H), 2.18 - 1.86 (m, 1H).
[0427] Compound 62. 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide
[0428] TIFF2024544507000066.tif39166
[0429] Compound 62 was synthesized in the same manner as compound 1, except that 5-(4-chlorophenyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0430] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 8.71 (t, J = 6.3 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.64 - 7.59 (m, 2H), 7.54 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.46 - 7.40 (m, 2H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.54 (d, J = 6.2 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.85 (d, J = 7.3 Hz, 2H), 2.92 (m, 1H), 2.60 (m, 1H), 2.39 (m, 1H), 2.10 (s, 3H), 2.02 (m, 2H), 0.70 (d, J = 6.7 Hz, 6H).
[0431] Compound 63. 5-(3-chlorophenyl)-1-cyclopropyl-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide
[0432] TIFF2024544507000067.tif32166
[0433] Compound 63 was synthesized in the same manner as compound 1, using 5-(3-chlorophenyl)-1-cyclopropyl-4-methyl-1H-pyrazole-3-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0434] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 8.72 (t, J = 6.4 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.63 - 7.56 (m, 3H), 7.53 (s, 1H), 7.49 - 7.42 (m, 2H), 5.11 (dd, J = 13.3, 5.0 Hz, 1H), 4.53 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.66 (m, 1H), 2.92 (m, 1H), 2.60 (m, 1H), 2.44 - 2.29 (m, 1H), 2.13 (s, 3H), 2.00 (m, 1H), 1.01 (m, 2H), 0.87 (m, 2H).
[0435] Compound 64. 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide
[0436] TIFF2024544507000068.tif32166
[0437] Compound 64 was synthesized in the same manner as compound 1, except that 5-(3-chlorophenyl)-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0438] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 8.80 (t, J = 6.2 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.64 - 7.58 (m, 2H), 7.54 (m, 2H), 7.47 (d, J = 7.9 Hz, 1H), 7.39 (m, 1H), 5.11 (dd, J = 13.3, 5.1 Hz, 1H), 4.97 (q, J = 8.9 Hz, 2H), 4.56 (d, J = 6.3 Hz, 2H), 4.46 (d, J = 17.4 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.92 (m, 1H), 2.64 - 2.56 (m, 1H), 2.38 (m, 1H), 2.11 (s, 3H), 2.04 - 1.99 (m, 1H).
[0439] Compound 65. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzo[b]thiophene-2-carboxamide
[0440] TIFF2024544507000069.tif32166
[0441] Compound 65 was synthesized in the same manner as compound 1, except that 5-methoxybenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0442] 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.39 (t, J = 6.3 Hz, 1H), 8.05 (s, 1H), 7.89 (d, J = 8.9 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.44 (s, 1H), 7.11 (d, J = 2.3 Hz, 1H), 5.10 (dd, J = 13.3, 5.0 Hz, 1H), 4.60 (d, J = 5.9 Hz, 2H), 4.50 - 4.41 (m, 1H), 4.36 - 4.27 (m, 1H), 3.83 (s, 3H), 2.97 - 2.84 (m, 1H), 2.64 - 2.55 (m, 1H), 2.45 - 2.33 (m, 1H), 2.04 - 1.95 (m, 1H).
[0443] Compound 66. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide
[0444] TIFF2024544507000070.tif32166
[0445] Compound 66 was synthesized in the same manner as compound 1, except that 6-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0446] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.36 (t, J = 6.0 Hz, 1H), 8.09 (s, 1H), 7.83 (d, J = 9.2 Hz, 2H), 7.71 (d, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 5.10 (dd, J = 13.4, 4.9 Hz, 1H), 4.60 (d, J = 5.8 Hz, 2H), 4.50 - 4.41 (m, 1H), 4.36 - 4.27 (m, 1H), 2.97 - 2.84 (m, 1H), 2.64 - 2.55 (m, 1H), 2.44 (s, 3H), 2.42 - 2.31 (m, 1H), 2.03 - 1.95 (m, 1H).
[0447] Compound 67. 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide
[0448] TIFF2024544507000071.tif32166
[0449] Compound 67 was synthesized in the same manner as compound 1, except that 3-chloro-6-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0450] 1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 9.05 (t, J = 6.5 Hz, 1H), 7.91 (s, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 5.12 (dd, J = 13.0, 4.8 Hz, 1H), 4.64 (d, J = 6.0 Hz, 2H), 4.52 - 4.43 (m, 1H), 4.38 - 4.29 (m, 1H), 2.98 - 2.86 (m, 1H), 2.65 - 2.56 (m, 1H), 2.48 (s, 3H), 2.44 - 2.36 (m, 1H), 2.05 - 1.97 (m, 1H).
[0451] Compound 68. 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzo[b]thiophene-2-carboxamide
[0452] TIFF2024544507000072.tif39166
[0453] Compound 68 was synthesized in the same manner as compound 1, except that 3-chloro-6-methoxybenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0454] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 8.94 (t, J = 6.1 Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.70-7.66 (m, 1H), 7.59 (s, 1H), 7.55-7.48 (m, 1H), 7.19 (dd, J = 8.9, 2.4 Hz, 1H), 5.15-5.06 (m, 1H), 4.63 (d, J = 5.9 Hz, 2H), 4.51-4.42 (m, 1H), 4.37-4.28 (m, 1H), 3.86 (s, 3H), 2.97-2.85 (m, 1H), 2.64-2.55 (m, 1H), 2.46-2.31 (m, 1H), 2.04-1.96 (m, 1H).
[0455] Compound 69. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5,6-dimethoxybenzo[b]thiophene-2-carboxamide
[0456] TIFF2024544507000073.tif32166
[0457] Compound 69 was synthesized in the same manner as compound 1, using 5,6-dimethoxybenzo[b]thiophene-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0458] 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.27 (t, J = 6.5 Hz, 1H), 7.98 (s, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.57 (s, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 5.11 (dd, J = 13.4, 5.0 Hz, 1H), 4.59 (d, J = 5.9 Hz, 2H), 4.50-4.41 (m, 1H), 4.36-4.28 (m, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 2.97-2.85 (m, 1H), 2.64-2.55 (m, 1H), 2.45-2.35 (m, 1H), 2.04-1.96 (m, 1H).
[0459] Compound 70. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-(trifluoromethyl)benzo[b]thiophene-2-carboxamide
[0460] TIFF2024544507000074.tif32166
[0461] Compound 70 was synthesized in the same manner as compound 1, using 4-(trifluoromethyl)benzo[b]thiophene-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0462] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.70 (m, 1H), 8.41 (m, 2H), 7.86 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 4.9 Hz, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.47 (d, J = 17.3 Hz, 1H), 4.33 (d, J = 17.4 Hz, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.43 - 2.27 (m, 1H), 2.01 (m, 1H).
[0463] Compound 71. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-(trifluoromethyl)benzo[b]thiophene-2-carboxamide
[0464] TIFF2024544507000075.tif39166
[0465] Compound 71 was synthesized in the same manner as compound 1, except that 7-(trifluoromethyl)benzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0466] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.60 (m, 1H), 8.31 (m, 1H), 7.92 (d, J = 7.5 kjHz, 1H), 7.77 - 7.63 (m, 2H), 7.59 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.2, 4.9 Hz, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.34 (d, J = 16.0, 1H), 2.91 (m, 1H), 2.60 (m, 1H), 2.42 - 2.32 (m, 1H), 2.00 (m, 1H).
[0467] Compound 72. 3-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-(trifluoromethyl)benzo[b]thiophene-2-carboxamide
[0468] TIFF2024544507000076.tif39166
[0469] Compound 72 was synthesized in the same manner as compound 1, except that 3-chloro-6-(trifluoromethyl)benzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0470] 1H NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 9.26 (m, 1H), 8.71 (s, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 5.12 (dd, J = 13.3, 4.9 Hz, 1H), 4.66 (d, J = 5.4 Hz, 2H), 4.48 (d, J = 17.2 Hz, 1H), 4.34 (d, J = 17.4 Hz, 1H), 3.00 - 2.83 (m, 1H), 2.65 - 2.58 (m, 1H), 2.40 (m, 1H), 2.08 - 1.94 (m, 1H).
[0471] Compound 73. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-(trifluoromethyl)benzo[b]thiophene-2-carboxamide
[0472] TIFF2024544507000077.tif32166
[0473] Compound 73 was synthesized in the same manner as compound 1, except that 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0474] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.60 (m, 1H), 8.41 (s, 1H), 8.34 - 8.25 (m, 2H), 7.75 (dd, J = 17.5, 8.2 Hz, 2H), 7.59 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 4.8 Hz, 1H), 4.63 (d, J = 5.8 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.60 (m, 1H), 2.39 (m, 1H), 2.00 (m, 1H).
[0475] Compound 74. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methoxybenzo[b]thiophene-2-carboxamide
[0476] TIFF2024544507000078.tif32166
[0477] Compound 74 was synthesized in the same manner as compound 1, using 4-methoxybenzo[b]thiophene-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0478] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.58 - 9.36 (m, 1H), 8.28 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.56 (d, J = z6.9 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.42 (t, J = 8.1 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.3, 4.9 Hz, 1H), 4.59 (d, J = 5.8 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.4 Hz, 1H), 3.95 (s, 3H), 3.01 - 2.83 (m, 1H), 2.60 (m, 1H), 2.44 - 2.32 (m, 1H), 2.07 - 1.92 (m, 1H).
[0479] Compound 75. 5-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide
[0480] TIFF2024544507000079.tif32166
[0481] Compound 75 was synthesized in the same manner as compound 1, except that 5-chloro-3-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0482] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.10 - 8.90 (m, 1H), 8.06 (d, J = 8.6 Hz, 1H), 7.98 (m, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.54 - 7.45 (m, 2H), 5.12 (dd, J = 13.5, 4.9 Hz, 1H), 4.60 (d, J = 5.8 Hz, 2H), 4.47 (d, J = 17.4 Hz, 1H), 4.33 (d, J = 17.3 Hz, 1H), 2.98 - 2.86 (m, 1H), 2.60 (m, 4H), 2.47 - 2.32 (m, 1H), 1.99 (m, 1H).
[0483] Compound 76. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide
[0484] TIFF2024544507000080.tif32166
[0485] Compound 76 was synthesized in the same manner as compound 1, except that 3-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0486] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 8.93 (t, J = 6.0 Hz, 1H), 8.07 - 7.95 (m, 1H), 7.94 - 7.84 (m, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.54 - 7.46 (m, 3H), 5.12 (dd, J = 13.5, 4.9 Hz, 1H), 4.60 (d, J = 5.9 Hz, 2H), 4.47 (d, J = 17.3 Hz, 1H), 4.33 (d, J = 17.3 Hz, 1H), 3.00 - 2.83 (m, 1H), 2.62 (m, 4H), 2.44 - 2.30 (m, 1H), 2.06 - 1.96 (m, 1H).
[0487] Compound 77. 4-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide
[0488] TIFF2024544507000081.tif32166
[0489] Compound 77 was synthesized in the same manner as compound 1, except that 4-chloro-3-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0490] 1H NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 9.14 (m, 1H), 8.08 - 7.96 (m, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.52 - 7.47 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 5.12 (dd, J = 13.4, 4.9 Hz, 1H), 4.60 (d, J = 5.8 Hz, 2H), 4.48 (d, J = 17.2 Hz, 1H), 4.34 (d, J = 17.4 Hz, 1H), 2.98 - 2.87 (m, 1H), 2.82 (s, 3H), 2.61 (m, 1H), 2.40 (m, 1H), 2.06 - 1.96 (m, 1H).
[0491] Compound 78. 7-Chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide
[0492] TIFF2024544507000082.tif39166
[0493] Compound 78 was synthesized in the same manner as compound 1, except that 7-chloro-3-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0494] 1H NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 9.06 (m, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.58 (s, 1H), 7.56 - 7.48 (m, 2H), 5.12 (dd, J = 13.4, 5.0 Hz, 1H), 4.60 (d, J = 5.9 Hz, 2H), 4.48 (d, J = 17.4 Hz, 1H), 4.33 (d, J = 17.4 Hz, 1H), 3.02 - 2.86 (m, 1H), 2.64 (m, 4H), 2.43 - 2.31 (m, 1H), 2.01 (m, 1H).
[0495] Compound 79. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-fluoro-3-methylbenzo[b]thiophene-2-carboxamide
[0496] TIFF2024544507000083.tif32166
[0497] Compound 79 was synthesized in the same manner as compound 1, except that 4-fluoro-3-methylbenzo[b]thiophene-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0498] 1H NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 9.06 (m, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.58 (s, 1H), 7.49 (m, 2H), 7.23 (dd, J = 12.2, 8.1 Hz, 1H), 5.12 (dd, J = 13.4, 4.9 Hz, 1H), 4.59 (d, J = 5.8 Hz, 2H), 4.47 (d, J = 17.3 Hz, 1H), 4.33 (d, J = 17.3 Hz, 1H), 2.99 - 2.85 (m, 2H), 2.72 (s, 3H), 2.61 (m, 1H), 2.46 - 2.35 (m, 1H), 2.01 (m, 1H).
[0499] Compound 80. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide
[0500] TIFF2024544507000084.tif32166
[0501] Compound 80 was synthesized in the same manner as compound 1, except that 3-methylbenzofuran-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0502] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.28 - 9.20 (m, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.63 - 7.56 (m, 2H), 7.49 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 5.11 (dd, J = 13.2, 5.0 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.2 Hz, 1H), 2.98 - 2.82 (m, 1H), 2.55 (s, 4H), 2.38 (m, 1H), 2.00 (m, 1H).
[0503] Compound 81. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzofuran-2-carboxamide
[0504] TIFF2024544507000085.tif32166
[0505] Compound 81 was synthesized in the same manner as compound 1, except that 5-methoxybenzofuran-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0506] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.36 (m, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.60 - 7.44 (m, 4H), 7.28 (m, 1H), 7.06 (m, 1H), 5.11 (dd, J = 13.5, 4.9 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 3.81 (s, 3H), 2.98 - 2.84 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 2.06 - 1.95 (m, 1H).
[0507] Compound 82. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-methoxybenzofuran-2-carboxamide
[0508] TIFF2024544507000086.tif39166
[0509] Compound 82 was synthesized in the same manner as compound 1, using 7-methoxybenzofuran-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0510] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.25 (m, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.56 (s, 1H), 7.52 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.21 (s, 1H), 6.98 (dd, J = 8.6, 2.1 Hz, 1H), 5.11 (dd, J = 13.2, 4.9 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 3.84 (s, 3H), 2.91 (m, 1H), 2.60 (m, 1H), 2.38 (m, 1H), 2.04 - 1.93 (m, 1H).
[0511] Compound 83. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzofuran-2-carboxamide
[0512] TIFF2024544507000087.tif32166
[0513] Compound 83 was synthesized in the same manner as compound 1, except that 6-methoxybenzofuran-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0514] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.46 - 9.25 (m, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.57 (m, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.26 (t, J = 7.9 Hz, 1H), 7.08 (d, J = 7.8 Hz, 1H), 5.11 (dd, J = 13.4, 4.9 Hz, 1H), 4.59 (d, J = 6.0 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 3.97 (s, 3H), 3.02 - 2.82 (m, 1H), 2.60 (m, 1H), 2.36 (m, 1H), 2.00 (m, 1H).
[0515] Compound 84. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3,6-dimethylbenzofuran-2-carboxamide
[0516] TIFF2024544507000088.tif32166
[0517] Compound 84 was synthesized in the same manner as compound 1, using 3,6-dimethylbenzofuran-2-carboxylic acid instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0518] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.17 (t, J = 6.2 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.56 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 4.9 Hz, 1H), 4.57 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.3 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.99 - 2.85 (m, 1H), 2.60 (m, 1H), 2.51 (s, 3H), 2.47 (s, 3H), 2.41 - 2.32 (m, 1H), 2.07 - 1.94 (m, 1H).
[0519] Compound 85. 5-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide
[0520] TIFF2024544507000089.tif32166
[0521] Compound 85 was synthesized in the same manner as compound 1, except that 5-bromo-3-methylbenzofuran-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0522] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.38 - 9.27 (m, 1H), 8.01 (m, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.66 - 7.54 (m, 3H), 7.49 (d, J = 7.8 Hz, 1H), 5.11 (dd, J = 13.4, 4.9 Hz, 1H), 4.57 (d, J = 6.1 Hz, 2H), 4.45 (d, J = 17.2 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.90 (m, 1H), 2.60 (m, 1H), 2.51 (s, 3H), 2.37 (m, 1H), 2.10 - 1.94 (m, 1H).
[0523] Compound 86. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)naphtho[2,1-b]furan-2-carboxamide
[0524] TIFF2024544507000090.tif32166
[0525] Compound 86 was synthesized in the same manner as compound 1, except that naphtho[2,1-b]furan-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0526] 1H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.45 (t, J = 6.2 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.27 (s, 1H), 8.09 (d, J = 8.1 Hz, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.70 (m, 2H), 7.60 (m, 2H), 7.52 (d, J = 7.9 Hz, 1H), 5.11 (dd, J = 13.4, 4.9 Hz, 1H), 4.64 (d, J = 6.0 Hz, 2H), 4.46 (d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 2.98 - 2.83 (m, 1H), 2.60 (m, 1H), 2.42 - 2.29 (m, 1H), 2.06 - 1.92 (m, 1H).
[0527] <Comparative Example 1. Synthesis and physicochemical properties of comparative isoindolinone derivatives having a glutarimide nucleus>
[0528] The physicochemical properties of the comparative compounds 1 to 3 are as follows.
[0529] Comparative compound 1. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoquinoline-3-carboxamide
[0530] TIFF2024544507000091.tif32166
[0531] Comparative compound 1 was synthesized in the same manner as compound 1, except that isoquinoline-3-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0532] 1H NMR (500 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.62 (t, J = 6.4 Hz, 1H), 9.41 (s, 1H), 8.59 (s, 1H), 8.27 (d, J = 8.1 Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 7.89 (t, J = 7.5 Hz, 1H), 7.85 - 7.79 (m, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.58 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 5.10 (dd, J = 13.3, 5.1Hz, 1H), 4.68 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.3 Hz, 1H), 4.30 (d, J = 17.3 Hz, 1H), 2.98 - 2.84 (m, 1H), 2.59 (m, 1H), 2.37 (m, 1H), 2.03 - 1.92 (m, 1H).
[0533] Comparative compound 2. N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)quinoxaline-2-carboxamide
[0534] TIFF2024544507000092.tif32166
[0535] Comparative compound 2 was synthesized in the same manner as compound 1, except that quinoxaline-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0536] 1H NMR (500 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.77 (t, J = 6.4 Hz, 1H), 9.50 (s, 1H), 8.22 (m, 2H), 8.04 - 7.98 (m, 2H), 7.70 (d, J = 7.8 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 5.10 (dd, J = 13.3, 5.1 Hz, 1H), 4.69 (d, J = 6.4 Hz, 2H), 4.44 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.3 Hz, 1H), 2.91 (m, 1H), 2.59 (m, 1H), 2.43 - 2.32 (m, 1H), 2.06 - 1.95 (m, 1H).
[0537] Comparative compound 3. 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)quinoline-2-carboxamide
[0538] TIFF2024544507000093.tif32166
[0539] Comparative compound 3 was synthesized in the same manner as compound 1, except that 6-chloroquinoline-2-carboxylic acid was used instead of 6-chloro-1H-indazole-3-carboxylic acid.
[0540] 1H NMR (300 MHz, DMSO) δ 10.98 (s, 1H), 9.65 (t, J = 6.4 Hz, 1H), 8.57 (d, J = 8.5 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 9.1 Hz, 1H), 7.90 (dd, J = 9.0, 2.4 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.53 (dd, J = 7.8, 1.4 Hz, 1H), 5.11 (dd, J = 13.2, 5.1 Hz, 1H), 4.69 (d, J = 6.3 Hz, 2H), 4.45 (d, J = 17.4 Hz, 1H), 4.31 (d, J = 17.4 Hz, 1H), 2.99 - 2.84 (m, 1H), 2.59 (m, 1H), 2.35 (m, 1H), 2.06 - 1.94 (m, 1H).
[0541] <Experimental Example 1. Evaluation of substrate proteolytic activity against CRBN>
[0542] In order to confirm whether the compounds of the present invention can specifically bind to CRBN (cereblon) and inhibit the function of CRBN, we investigated the effect of the compounds on the degradation activity of Ikaros (IKZF1) protein (Chamberlain, PP et al., 2014) or GSPT1 protein (Matyskiela, ME et al., 2016), which is degraded by CRBN protein when bound to thalidomide and its analogs.
[0543] In order to evaluate the activity of the compound according to the present invention to degrade Ikaros (IKZF1) protein or GSPT1 protein, the following experiment was carried out.
[0544] 5 × 10 KG-1 cells in a 12-well plate 5After seeding the cells, each well was treated with each compound at a specified concentration. After 6 hours, cell lysates were collected using TBSN buffer. Ikaros proteolytic activity was evaluated by Western blot using an antibody against Ikaros protein, and GSPT1 proteolytic activity was evaluated by Western blot using an antibody against GSPT1 protein. To evaluate Ikaros proteolytic activity, the same amount of protein was loaded into each well of a 4-15% gradient gel, and after electrophoresis, the protein was transferred to a PVDF membrane and bound to the primary antibody against each protein. Then, a secondary antibody with HRP was bound and developed using HRP substrate.
[0545] As a result, as shown in FIG. 1, it was confirmed that compound 10 of the present invention selectively promotes the degradation of GSPT1 protein when treated with KG-1 cell line for 6 hours.
[0546] <Experimental Example 2. Cytotoxicity Experiment>
[0547] In order to confirm the effect of the compound of the present invention on cancer cells, a cytotoxicity experiment was carried out as follows.
[0548] Cancer cells (KG-1) were dispensed into a 96-well plate at 10,000 cells per well, and treated with the compounds of the present invention and comparative substances (comparative substances; comparative compounds 1, 2, and 3) at predetermined concentrations. After 72 hours, WST-1 reagent was added, and after 1 hour, the degree of cancer cell death was measured by measuring the absorbance at 450 nm using a Spectramax spectrophotometer. The IC was calculated using the measured value with the Graphpad Prism program. 50 The values (μM) were calculated and are shown in Table 1.
[0549] The viability of NCI-H1155 (lung cancer cells) was measured using a CytoX cell viability assay kit (LPS solution, #CYT3000). NCI-H1155 cells were seeded in a 12-well plate, and then treated with each of the present invention's example compounds and the comparative substance (CC-90009) at 10 nM and 500 nM concentrations for 72 hours. After that, the cells were added with CytoX solution and cultured for 1 hour, and the absorbance of each well was measured at 450 nm using a microplate reader, and the % viability was calculated and shown in Table 2.
[0550] [Table 1]
[0551] [Table 2]
[0552] As seen in Tables 1 and 2, the compounds of the present invention having a heteroaryl amide structure have excellent cytotoxicity in cancer cells. In particular, from the structure-activity comparison of the compounds of the present invention, it was confirmed that the cytotoxic activity against KG-1 and NCI-H1155 cancer cells is superior when R1 is a bicyclic heteroaryl (compounds 3, 7, and 10) compared to when R1 is a monocyclic aryl (comparative substance) or heteroaryl (compounds 37 and 38).
[0553] Among the compounds in which R1 is a (6+5)-angled bicyclic heteroaryl, when R1 is indole, indazole, benzimidazole, benzisoxazole, benzoxazole, benzothiazole, benzofuran, and benzothiophene (compounds 3, 4, 6-10, 26, 33, 34, 36, 44, 56, 57, 65-84), it was confirmed that the cytotoxic activity against KG-1 and cancer cells is superior to that of the compounds in which R1 is substituted with quinoline, isoquinoline, and quinoxaline, which are (6+6)-angled bicyclic heteroaryls (compounds 1-3).
[0554] It was confirmed that when R1 is a monocyclic heteroaryl and R2 has an aryl substituent, the cytotoxic activity is significantly superior. Among compounds with similar overall structures, it was confirmed that compounds in which R1 is a monocyclic heteroaryl and R2 simultaneously has an aryl substituent (compounds 2, 5, 11, 13-15, 17-21, 23, 25, 29, 32, 39, 40, 45, and 46) have superior cytotoxic activity against cancer cells compared to compounds that do not have such a structure (compounds 30 and 38).
[0555] In addition, among compounds with similar overall structures, compounds in which R1 is a monocyclic heteroaryl and R2 simultaneously has an aryl substituent (compounds 17, 23, 39, and 40) were found to have significantly superior activity compared to compounds in which R1 is a bicyclic heteroaryl (compounds 8, 9, and 26).
[0556] From the H1155 cells (% viability) in Table 2, it was confirmed that the (6+5)-angled bicyclic heteroaryl compounds (compounds 56-58, 62-70) had better cytotoxic activity against cancer cells than the compounds where R1 is a (6+6)-angled bicyclic heteroaryl (compounds 59, 60, 61) as shown in Table 1.
[0557] <Formulation Example 1. Production of Powder>
[0558] The compound of the present invention (12 g) and lactose (1 g) were mixed and filled into an airtight pack to prepare a powder.
[0559] <Formulation Example 2. Tablet Production>
[0560] The compound of the present invention (1100 mg), microcrystalline cellulose (100 mg), lactose hydrate (60 mg), low-substituted hydroxypropylcellulose (20 mg), and magnesium stearate (2 mg) were mixed and compressed into tablets by a conventional tablet manufacturing method.
[0561] <Formulation Example 3. Production of Capsules>
[0562] After mixing 1,100 mg of the compound of the present invention, 100 mg of microcrystalline cellulose, 60 mg of lactose hydrate, 20 mg of low-substituted hydroxypropylcellulose, and 2 mg of magnesium stearate, the above ingredients were mixed and filled into gelatin capsules according to a conventional capsule manufacturing method to produce capsules.
[0563] <Formulation Example 4. Manufacturing of pills>
[0564] 190 mg of the compound of the present invention, 5 mg of glutinous rice starch, 5 mg of purified water, and a small amount of dextrin, maltodextrin, corn starch, and microcrystalline cellulose (MCC) as additives to inhibit hygroscopicity were mixed and then made into 100 mg pills by a conventional method.
[0565] <Formulation Example 5. Manufacture of injections>
[0566] 110 mg of the compound of the present invention, an appropriate amount of sterile distilled water for injection, and an appropriate amount of a pH adjusting agent were mixed, and then prepared into an ampoule (2 ml) having the above-mentioned ingredient contents according to a conventional manufacturing method for injection.
Claims
1. The following chemical formula 1: [Formula 1] (In the formula, l is an integer from 0 to 3; n is an integer of 0 or 1; p is an integer of 1 or 2; R 1 is C 5-13 Heteroaryl, C 6-10 Aryl, C 4-10 Cycloalkyl, C 4-10 is heterocycloalkyl; R 2 are independently hydrogen, halogen, ketone, C 1-5 Alkyl, C 1-3 Alkoxy, HaloC 1-3 Alkyl, haloC 1-3 Alkoxy, C 3-6 substituted with one or more substituents selected from the group consisting of cycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted benzyl; wherein the substituted phenyl or benzyl is halogen or C 1-5 substituted with one or more substituents selected from the group consisting of alkyl; R 3 is replaced with hydrogen or deuterium (D; deuterium); It is displayed as 1. A compound, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof, comprising:
2. In the above formula 1, R 1 is substituted with one substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, indazolyl, benzimidazolyl, benzofuranyl, benzopyridinyl, benzopyranyl, benzopyridazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, and naphthofuranyl.
2. The compound according to claim 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.
3. In the above formula 1, R 1 is C 5-13 is heteroaryl; R 2 is substituted with one or more substituents selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted benzyl; wherein the substituted phenyl or benzyl is halogen or C 1-5 substituted with one or more substituents selected from the group consisting of alkyl; 2. The compound of claim 1, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.
4. In the above formula 1, R 1 is substituted with one substituent selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, indolyl, indazolyl, benzimidazolyl, benzofuranyl, benzopyridinyl, benzopyranyl, benzopyridazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, and naphthofuranyl.
4. The compound according to claim 3, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.
5. The compound of formula 1 above is 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (Compound 1); 3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 2); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide (compound 3); 5,6-dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 4); 3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 5); 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide (compound 6); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-3-carboxamide (compound 7); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 8); 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indole-2-carboxamide (compound 9); 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]isoxazole-3-carboxamide (compound 10); 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide (compound 11); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 12); 3-(3,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 13); 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrrole-2-carboxamide (compound 14); 1-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (compound 15); 5,6-dichloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-benzo[d]imidazole-2-carboxamide (compound 16); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide (compound 17); 4-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide (compound 18); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)isoxazole-3-carboxamide (compound 19); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)pyrimidine-2-carboxamide (compound 20); 1-benzyl-5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 21); 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)picolinamide (compound 22); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-5-phenyl-1H-pyrazole-3-carboxamide (compound 23); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-3-phenyl-1H-pyrazole-5-carboxamide (compound 24); 5-(2,4-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 25); 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]thiazole-2-carboxamide (compound 26); 4-bromo-3-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-5-carboxamide (compound 27); 5-(2,5-dichlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 28); 5-(2,4-dimethylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-pyrazole-3-carboxamide (compound 29); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1′-biphenyl]-3-carboxamide (compound 30); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methylpicolinamide (compound 31); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 32); 6-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]oxazole-2-carboxamide (compound 33); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1H-indazole-3-carboxamide (compound 34); 3-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrazole-5-carboxamide (compound 35); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-indazole-3-carboxamide (compound 36); 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-imidazole-2-carboxamide (compound 37); 4-Bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide (compound 38); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-4-phenyl-1H-pyrrole-2-carboxamide (compound 39); 4-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-methyl-1H-pyrrole-2-carboxamide (compound 40); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide (compound 41); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-phenyl-1H-pyrazole-3-carboxamide (compound 42); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-(4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 43); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[d]thiazole-2-carboxamide (compound 44); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methyl-4-phenylpicolinamide (compound 45); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-phenylpicolinamide (compound 46); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-phenylpyrazine-2-carboxamide (compound 47); 3-(2-chloro-6-fluorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methylisoxazole-4-carboxamide (compound 48); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-phenyl-1H-pyrazole-5-carboxamide (compound 49); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide (compound 50); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1′-biphenyl]-4-carboxamide (compound 51); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-[1,1′-biphenyl]-2-carboxamide (compound 52); 1-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)cyclopentane-1-carboxamide (compound 53); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-phenylcyclopentane-1-carboxamide (compound 54); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-1-phenylpyrrolidine-3-carboxamide (compound 55); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzofuran-2-carboxamide (compound 56); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxy-1H-indole-2-carboxamide (compound 57); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)benzo[b]thiophene-2-carboxamide (compound 58); 7-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-hydroxyquinoline-3-carboxamide (compound 59); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-oxo-2H-chromene-3-carboxamide (compound 60); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)chromene-4-carboxamide (compound 61); 5-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-1-isobutyl-4-methyl-1H-pyrazole-3-carboxamide (compound 62); 5-(3-chlorophenyl)-1-cyclopropyl-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1H-pyrazole-3-carboxamide (compound 63); 5-(3-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide (compound 64); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzo[b]thiophene-2-carboxamide (compound 65); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide (compound 66); 3-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methylbenzo[b]thiophene-2-carboxamide (compound 67); 3-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzo[b]thiophene-2-carboxamide (compound 68); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5,6-dimethoxybenzo[b]thiophene-2-carboxamide (compound 69); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 70); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 71); 3-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 72); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-(trifluoromethyl)benzo[b]thiophene-2-carboxamide (compound 73); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-methoxybenzo[b]thiophene-2-carboxamide (compound 74); 5-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 75); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 76); 4-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 77); 7-chloro-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzo[b]thiophene-2-carboxamide (compound 78); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-4-fluoro-3-methylbenzo[b]thiophene-2-carboxamide (compound 79); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide (compound 80); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-5-methoxybenzofuran-2-carboxamide (compound 81); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-7-methoxybenzofuran-2-carboxamide (compound 82); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-6-methoxybenzofuran-2-carboxamide (compound 83); N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3,6-dimethylbenzofuran-2-carboxamide (compound 84); 5-bromo-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-methylbenzofuran-2-carboxamide (compound 85); and N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)naphtho[2,1-b]furan-2-carboxamide (compound 86); Selected from the group consisting of 3. A compound according to claim 1 or 2, an optical isomer thereof, or a pharma- ceutically acceptable salt thereof.
6. The compound represented by formula 1 or a pharma- ceutical acceptable salt thereof according to claim 1 or 2 is contained as an active ingredient.
1. A pharmaceutical composition for preventing or treating leprosy, chronic graft-versus-host disease, inflammatory disease or cancer, comprising:
7. The cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, small cell carcinoma, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, paraanal cancer, colon cancer, breast cancer, trumpeteran carcinoma, endometrial carcinoma, cervical cancer, vaginal cancer, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma. The pharmaceutical composition according to claim 6 for preventing or treating leprosy, chronic graft-versus-host disease, inflammatory diseases or cancer.
Citation Information
Patent Citations
5-substituted isoindoline compounds
JP2010502627A
5-substituted isoindoline compounds
JP2011522803A
Isoindoline compounds for use in cancer treatment
JP2012507541A
Novel piperidine-2,6-dione derivatives and their uses
JP2020519582A
Low molecular weight proteolytic substances and their applications
JP2023541522A
